登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《BioRxiv，4月12日，Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-13

  • Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro

    Hongbo Liu, Fei Ye, Qi Sun, Hao Liang, Chunmei Li, Roujian Lu, Baoying Huang, Wenjie Tan, View ORCID ProfileLuhua Lai

    doi: https://doi.org/10.1101/2020.04.10.035824

    Abstract

    COVID-19 has become a global pandemic that threatens millions of people worldwide. There is an urgent call for developing effective drugs against the virus (SARS-CoV-2) causing this disease. The main protease of SARS-CoV-2, 3C-like protease (3CLpro), is highly conserved across coronaviruses and is essential for the maturation process of viral polyprotein. Scutellariae radix (Huangqin in Chinese), the root of Scutellaria baicalensis has been widely used in traditional Chinese medicine to treat viral infection related symptoms. The extracts of S. baicalensis have exhibited broad spectrum antiviral activities. We studied the anti-SARS-CoV-2 activity of S. baicalensis and its ingredient compounds. We found that the ethanol extract of S. baicalensis inhibits SARS-CoV-2 3CLpro activity in vitro and the replication of SARS-CoV-2 in Vero cells with an EC50 of 0.74 μg/ml. Among the major components of S. baicalensis, baicalein strongly inhibits SARS-CoV-2 3CLpro activity with an IC50 of 0.39 μM. We further identified four baicalein analogue compounds from other herbs that inhibit SARS-CoV-2 3CLpro activity at microM concentration. Our study demonstrates that the extract of S. baicalensis has effective anti-SARS-CoV-2 activity and baicalein and analogue compounds are strong SARS-CoV-2 3CLpro inhibitors.

    *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.04.10.035824v1
211浏览量
原文链接
相关报告

  • 《4月12日_黄芩提取物和黄芩素可体外抑制SARS-CoV-2复制及3C样蛋白酶活性》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-13
    • 信息名称：黄芩提取物和黄芩素可体外抑制SARS-CoV-2复制及3C样蛋白酶活性 1.时间：2020年4月12日 2.机构或团队：北京大学、中国疾病预防控制中心病毒病预防控制所 3.事件概要： 北京大学等于2020年4月12日在bioRxiv上发表题为“Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro”的文章。文章指出，SARS-CoV-2的主要蛋白酶——3C样蛋白酶（3CLpro），在所有冠状病毒中高度保守，是病毒多聚蛋白成熟过程中必不可少的。黄芩的根在传统中医中被广泛用于治疗病毒感染相关病症。黄芩的提取物具有广谱抗病毒活性。作者研究了黄芩及其成分化合物的抗SARS-CoV-2活性，发现黄芩的乙醇提取物在体外抑制SARS-CoV-2 3CLpro的活性以及SARS-CoV-2在Vero细胞中的复制，EC50为0.74μg/ml。黄芩的主要成分黄芩素能强烈抑制SARS-CoV-2 3CLpro的活性，IC50为0.39μM。作者进一步从其他药材中发现的4种黄芩素类似物在microM的浓度下可抑制SARS-CoV-2 3CLpro的活性。作者指出，黄芩提取物具有有效的抗SARS-CoV-2活性，黄芩素及类似物是强的SARS-CoV-2 3CLpro的抑制剂。 4.附件： 原文链接 https://www.biorxiv.org/content/10.1101/2020.04.10.035824v1
    117浏览量
    原文链接

  • 《Nature，9月4日，Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-09-15
    • Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease Lifeng Fu, Fei Ye, Yong Feng, Feng Yu, Qisheng Wang, Yan Wu, Cheng Zhao, Huan Sun, Baoying Huang, Peihua Niu, Hao Song, Yi Shi, Xuebing Li, Wenjie Tan, Jianxun Qi & George Fu Gao Nature Communications volume 11, Article number: 4417 (2020) Abstract COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (Mpro, also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target. Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting Mpro. Moreover, combined application of GC376 with Remdesivir, a nucleotide analogue that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect. Further structural analysis reveals binding of both inhibitors to the catalytically active side of SARS-CoV-2 protease Mpro as main mechanism of inhibition. Our findings may provide critical information for the optimization and design of more potent inhibitors against the emerging SARS-CoV-2 virus.
    177浏览量
    原文链接